OBJECTIVES: Polymorphisms in promoter region of TNF-alpha gene were shown to interfere with the transcriptional activity of the gene resulting in the production of different levels of TNF-alpha product suggesting their involvement in susceptibility or severity of many inflammatory diseases. We set up a case-control study consisting of 117 COPD (Chronic Obstructive Pulmonary Disease), 62 DB (bronchiectasis) patients and two control groups (109 smokers without COPD-healthy smokers control group and 212 general population subjects) to evaluate involvement of TNF-alpha gene polymorphisms in the abovementioned diseases in a homogeneous population. METHODS: The novel methodology of the NanoChip Molecular Biology Workstation (MBW Nanogen http://www.nanogen.com) was employed to genotype the 5 promoter SNPs. RESULTS AND CONCLUSIONS: Genotype frequencies of the 5 SNPs showed no significant difference between the COPD and DB patient groups and the healthy smokers group. Statistical difference (p=0.043) was only revealed between the haplotype frequencies in COPD patients compared to the general population control group. The NanoChip MBW is an accurate method for SNP screening.
OBJECTIVES: Polymorphisms in promoter region of TNF-alpha gene were shown to interfere with the transcriptional activity of the gene resulting in the production of different levels of TNF-alpha product suggesting their involvement in susceptibility or severity of many inflammatory diseases. We set up a case-control study consisting of 117 COPD (Chronic Obstructive Pulmonary Disease), 62 DB (bronchiectasis) patients and two control groups (109 smokers without COPD-healthy smokers control group and 212 general population subjects) to evaluate involvement of TNF-alpha gene polymorphisms in the abovementioned diseases in a homogeneous population. METHODS: The novel methodology of the NanoChip Molecular Biology Workstation (MBW Nanogen http://www.nanogen.com) was employed to genotype the 5 promoter SNPs. RESULTS AND CONCLUSIONS: Genotype frequencies of the 5 SNPs showed no significant difference between the COPD and DB patient groups and the healthy smokers group. Statistical difference (p=0.043) was only revealed between the haplotype frequencies in COPDpatients compared to the general population control group. The NanoChip MBW is an accurate method for SNP screening.
Authors: Elizabeth Córdoba-Lanús; Rebeca Baz-Dávila; Juan P de-Torres; María C Rodríguez-Pérez; Nicole Maca-Meyer; Nerea Varo; Chaxiraxi Medina-Coello; Armando Aguirre-Jaime; Ciro Casanova Journal: BMC Med Genet Date: 2011-10-10 Impact factor: 2.103
Authors: Juan Manuel Reséndiz-Hernández; Raúl H Sansores; Rafael de Jesús Hernández-Zenteno; Gilber Vargas-Alarcón; Laura Colín-Barenque; Mónica Velázquez-Uncal; Angel Camarena; Alejandra Ramírez-Venegas; Ramcés Falfán-Valencia Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-06-29
Authors: Sangmi S Park; Jessica L Perez Perez; Brais Perez Gandara; Christina W Agudelo; Romy Rodriguez Ortega; Huma Ahmed; Itsaso Garcia-Arcos; Cormac McCarthy; Patrick Geraghty Journal: Medicina (Kaunas) Date: 2022-08-01 Impact factor: 2.948